A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Derek P. Wong,Nand K. Roy,Keman Zhang,Anusha Anukanth,Abhishek Asthana,Nicole J. Shirkey-Son,Samantha Dunmire,Bryan J. Jones,Walker S. Lahr,Beau R. Webber,Branden S. Moriarity,Paolo Caimi,Reshmi Parameswaran
DOI: https://doi.org/10.1038/s41467-021-27853-w
IF: 16.6
2022-01-11
Nature Communications
Abstract:Abstract B cell-activating factor (BAFF) binds the three receptors BAFF-R, BCMA, and TACI, predominantly expressed on mature B cells. Almost all B cell cancers are reported to express at least one of these receptors. Here we develop a BAFF ligand-based chimeric antigen receptor (CAR) and generate BAFF CAR-T cells using a non-viral gene delivery method. We show that BAFF CAR-T cells bind specifically to each of the three BAFF receptors and are effective at killing multiple B cell cancers, including mantle cell lymphoma (MCL), multiple myeloma (MM), and acute lymphoblastic leukemia (ALL), in vitro and in vivo using different xenograft models. Co-culture of BAFF CAR-T cells with these tumor cells results in induction of activation marker CD69, degranulation marker CD107a, and multiple proinflammatory cytokines. In summary, we report a ligand-based BAFF CAR-T capable of binding three different receptors, minimizing the potential for antigen escape in the treatment of B cell cancers.
multidisciplinary sciences
What problem does this paper attempt to address?